• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » DBV Technologies planning Viaskin Peanut global phase III trial in children

DBV Technologies planning Viaskin Peanut global phase III trial in children

June 25, 2015
CenterWatch Staff

DBV Technologies, a clinical-stage specialty biopharmaceutical company, has announced the completion of its End-of-Phase II meeting with the FDA. The outcome of this meeting on the clinical development plan for Viaskin Peanut is consistent with the previously announced positive opinion of the Pediatric Committee of the EMA on Viaskin Peanut’s Pediatric Investigation Plan (PIP).

BDBV Technologies plans to initiate a global phase III trial with Viaskin Peanut for the treatment of peanut allergic children 4 to 11 years of age in the fourth quarter of 2015. Additional development plans for Viaskin Peanut in younger and older patients will be discussed with the FDA in the second half of 2015.

The anticipated phase III trial, Peanut EPIT Efficacy and Safety Study (PEPITES) is expected to begin in the fourth quarter of 2015 following the submission of the final clinical trial protocol and updated chemistry, manufacturing and controls information, and review by the FDA, as well as review and approval of Clinical Trial Applications in the other countries where the trial is expected to be conducted.

In addition to the planned pivotal study, which is essential to support initial European Marketing Authorization Application (MAA) and initial U.S. Biologics License Application (BLA) filings, DBV also intends to conduct additional separate clinical trials in younger and older patients. DBV expects that further regulatory consultation will help to optimize the clinical development plan for assessing safety and efficacy of Viaskin Peanut in these patient populations.

PEPITES is planned as a randomized, double-blind, placebo-controlled pivotal phase III trial designed to assess the efficacy and safety of Viaskin Peanut 250μg in approximately 260 pediatric patients from 35 sites in North America (U.S. and Canada), Australia and Europe (Ireland and Germany). Patients will be randomized 2:1 to receive either Viaskin Peanut 250μg or placebo for 12 months. This planned phase III trial is designed to confirm with appropriate statistical considerations in children aged 4 to 11, Viaskin Peanut’s treatment effect that was shown during the phase IIb VIPES trial, while providing sufficient safety data to support initial registration fillings in this patient population.

During the trial, patients will be assessed using a double-blind, placebo controlled food challenge (DBPCFC). The primary endpoint for PEPITES is expected to be based on a more stringent treatment responder definition as compared to the criteria used in VIPES. The refined endpoint could potentially increase the clinical relevance by better defining the magnitude of the treatment effect. The FDA and EMA agreed to a combined primary endpoint based on a responder analysis after 12 months of treatment with Viaskin Peanut 250µg. For patients with a baseline peanut protein eliciting dose (ED) equal to or less than 10mg, a responder will be defined as a patient with a peanut protein ED equal to or greater than 300mg of peanut protein after 12 months of treatment. For subjects with a baseline ED greater than 10mg, a responder will be defined as a patient with a peanut protein eliciting dose equal to or greater than 1,000mg of peanut protein after 12 months of treatment.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing